CRVO - CervoMed, Inc. Debt to Book Capitalization Ratio

Corporate company logo of CervoMed Inc. (CRVO)

Monitoring the debt-to-equity ratio of CervoMed Inc. (CRVO) helps assess the development of its dementia drugs, with the value of 0.00 capturing the metric's level. The stability of supply chains for temperature-sensitive medications complements the high cost of research and strict FDA oversight, creating a defensive barrier for the biotech business in the US market.

CervoMed Corporation (CRVO) - Debts to Book Value from 02/21/2024 to 10/28/2026
Flagship merchandise of CervoMed Inc

Fundamental analysis of the debt load allows for an objective assessment of the issuer's resilience to market shocks. For CervoMed Inc. (CRVO), whose resources are focused on high-risk developments in dementia therapy, controlling financial leverage is critically important. The current ratio of debt to balance sheet capital demonstrates the proportion of borrowed funds relative to equity. An increase in this coefficient signals overheating and a reduction in the margin of safety. Sharp deviations on the chart indicate the company's dangerous dependence on external financing.

Who CervoMed Inc. competes with

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|Debts to Book Capitalization VKTX|Debt to Book Value supernus.com|Catalyst Pharmaceuticals, Inc. - Debts to Book Capitalization|Debts to Book Value DNLI (Denali)|Debt to Book Capitalization Ratio Harmony Pharma|BHVN - Debt to Net Assets Ratio|AMLX - Debt to Book Value|TRVI: Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio PRAX|AVXL (Anavex) - Debts to Book Value|Debt to Book Capitalization Ratio CBLL|Debt to Book Value prothena.com|Alector, Inc. - Debts to Book Capitalization|Debts to Book Value annexonbio.com (ANNX)|OMER - Debts to Book Capitalization|NGNE - Debt to Book Value Ratio|Debt to Book Value AC Immune Corp (ACIU)|VYGR - Debt to Net Assets Ratio|Neumora Therapeutics - Debts to Book Capitalization|SCLX (scilexholding.com) - Debts to Net Assets|Debt to Book Capitalization Ratio Tevogen Bio (TVGN)|Debt to Book Value Ratio Alpha Cognition Corp|Debts to Book Capitalization CGTX (Cognition Therapeutics)|Debt to Book Value Inhibikase Pharma IKT|Debt to Book Value SAVA|Debts to Net Assets Assertio Holdings ASRT|COYA: Debts to Book Capitalization|VTGN: Debt to Book Value|Debt to Book Capitalization Ratio ovidrx.com OVID|Debt to Net Assets Ratio Acumen Pharmaceuticals, Inc|Debt to Book Value Alterity Therapeutics Ltd.|Debt to Book Capitalization Ratio CLNN|PepGen Inc. - Debt to Book Capitalization Ratio|Debts to Book Value JUNS (Jupiter Neurosciences, Inc.)|RLMD - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Annovis Bio Corporation ANVS|GRCE (Grace Tx) - Debts to Book Capitalization|fireflyneuro.com (AIFF) - Debts to Book Value|KLTO: Debt to Book Value|NRSN (NeuroSense Therapeutics Ltd.) - Debts to Book Capitalization|RVPH - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio MTVA|NeurAxis, Inc. - Debt to Book Capitalization Ratio|Debts to Book Value heliusmedical.com (HSDT)|Passage Bio - Debts to Book Capitalization|Debt to Book Value Neuphoria Therapeutics, Inc. NEUP|NERV (Minerva Neurosciences Corp) - Debts to Book Capitalization|ATHA: Debts to Book Value|Debt to Book Capitalization Ratio Addex Therapeutics ADXN|Debt to Net Assets Ratio Alzamend Neuro|Debt to Book Value Cyclerion Therapeutics Inc.|Debt to Book Capitalization Ratio PTIX|Pasithea Therapeutics - Debt to Book Capitalization Ratio|Debts to Book Value CRGT (cortigent.com)|Avenue Therapeutics - Debt to Book Capitalization Ratio|Debt to Book Value brainstorm-cell.com BCLI|CARA (Cara Therapeutics) - Debts to Book Capitalization|CHRO - Debts to Book Value|Debts to Book Capitalization eliemtx.com|Debt to Book Value Ratio Intra-Cellular Therapies, Inc.|LBPH - Debt to Book Value|Debt to Net Assets Ratio marinuspharma.com|NKGN (NKGen Biotech) - Debts to Book Capitalization|Debts to Net Assets NRBO (NeuroBo Pharmaceuticals Inc)|SAGE - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Synaptogenix, Inc SNPX|TRVN: Debts to Book Capitalization|Vigil Neuroscience (VIGL) - Debt to Book Value|Anew Medical - Debt to Book Value|Cerevel Therapeutics Inc (CERE) - Debts to Net Assets